Get the Daily Brief
Latest Biotech News
Drug Pricing Policies and Market Dynamics Evolve in 2025
Pharmaceutical policy and market trends are shifting. The Trump administration finalizes Medicare Part D Most Favored Nation (MFN) rule, setting precedent for presidential drug price negotiations....
Biotech Financing and IPO Landscape Expands in Hong Kong
Investment activity is surging in Asia’s biotech sector. Eight companies have filed on the Hong Kong Stock Exchange with two seeking dual listings. NASDAQ firms Ocular, Ovid, and Palisade have...
Jazz-Roche Lung Cancer Combo Gains Early FDA Nod
The U.S. Food and Drug Administration has approved a first-line maintenance combination therapy for extensive-stage small-cell lung cancer. The combo includes Jazz Pharmaceuticals' Zepzelca...
Biopharma Layoffs Persist As Industry Faces Restructuring
The biopharmaceutical sector continues to experience significant workforce reductions, with 62 layoff rounds reported in Q3 2025, nearly matching the earlier quarters. Notable cuts include Novo...
AI-Driven Advances Accelerate Drug Discovery and Prognosis
Recent breakthroughs harness artificial intelligence to transform drug discovery and cancer prognosis. Nanyang Biologics plans a $1.5 billion Nasdaq SPAC combining machine learning with natural...
FDA Cell and Gene Therapy Listening Session Highlights Development Strategies
The FDA’s Office of Therapeutic Products convened a public listening session focusing on leveraging prior knowledge to streamline cell and gene therapy (CGT) product development and review....
New AI and Computing Models Propel Scientific Research Efficiency
Innovations in AI and computing are revolutionizing scientific productivity and research methodologies. Mercor’s AI Productivity Index benchmarks real-world AI economic value, engaging STEM...
Groundbreaking Molecular and Cellular Insights Illuminate Disease Mechanisms
Recent studies reveal novel molecular pathways impacting multiple diseases. EZH2 enzyme modulation affects T cell activation in liver cancer through the MIF-CD74 axis, impacting tumor immunity. A...
Innovations in Imaging and Genomic Technologies Enhance Disease Diagnosis
Technological advancements are improving the detection and characterization of complex diseases. Dovetail Genomics introduced LinkPrep™, combining DNA sequence with 3D genome architecture analysis...
FDA Approvals and Policy Updates Shape Biopharma Landscape
Key regulatory developments include FDA approval of a new generic medical abortion pill (mifepristone) and the addition of Jazz Pharmaceuticals and Roche’s lung cancer therapy combination some...
Herbal and Natural Compounds Show Promise in Disease Management
Research deepens understanding of traditional medicinal compounds in modern therapy. Atractylodes lancea demonstrates potential to improve cardio-renal function in metabolic syndrome models....
Jazz and Roche Win FDA Nod for Lung Cancer First-Line Maintenance
Jazz Pharmaceuticals and Roche secured FDA approval for a new combination therapy in extensive-stage small-cell lung cancer. The approval covers Zepzelca (lurbinectedin) combined with Tecentriq...
Biopharma Layoffs Persist Amidst Industry Restructuring in 2025
The biopharma sector continues to experience substantial workforce reductions in 2025, with 62 layoff rounds reported in the third quarter alone—nearly matching the 64 rounds recorded in each of...
Nanyang Biologics Pursues $1.5B Nasdaq SPAC to Boost Drug Discovery
Singapore-based Nanyang Biologics has entered a $1.5 billion business combination agreement with Nasdaq-listed RF Acquisition Corp II to facilitate its public listing. The company is building a...
FDA Approves Multiple Generic Versions of Mifepristone Amid Political Backlash
The U.S. Food and Drug Administration greenlit new generic versions of mifepristone, the medical abortion pill, including Evita Solutions' product deemed bioequivalent to the original Mifeprex....
OpenFold3: Pharma Leaders Pool Data to Accelerate AI-Driven Drug Discovery
Major pharmaceutical companies Bristol Myers Squibb, Takeda, and Astex have joined forces to pool proprietary structural biology data sets for training OpenFold3, an AI platform dedicated to drug...
Cartography Biosciences Secures $67M Series B to Advance T-Cell Therapies
Cartography Biosciences closed a $67 million Series B financing round supporting their pipeline development of bispecific and multispecific T-cell engaging antibodies targeting novel and...
AI Model CRISP Enhances Drug Response Predictions in Novel Cell Types
Researchers have developed CRISP, a cutting-edge computational framework enabling prediction of drug-induced perturbation responses at single-cell resolution across previously untested cell types....
Jazz Pharmaceuticals Advances Epilepsy Treatment with $550M Sovargen ASO Deal
Angelini Pharma has secured development and commercialization rights from Sovargen for SVG-105, an antisense oligonucleotide candidate targeting intractable epilepsy, through a $550 million...
FDA Cell and Gene Therapy Listening Session Highlights Regulatory Outlook
The U.S. FDA convened a public listening session engaging industry experts from GeneVentiv Therapeutics, Viralgen, and others to discuss leveraging prior knowledge for accelerated cell and gene...